Literature DB >> 17929014

Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.

Walter Jentzen1, Reiner Weise, Jürgen Kupferschläger, Lutz Freudenberg, Wolfgang Brandau, Ronald Bares, Wolfgang Burchert, Andreas Bockisch.   

Abstract

PURPOSE: This study evaluated the absolute quantification of iodine-124 ((124)I) activity concentration with respect to the use of this isotope for dosimetry before therapies with (131)I or (131)I-labeled radiotherapeuticals. The recovery coefficients of positron emission tomography(/computed tomography) PET(/CT) systems using (124)I were determined using phantoms and then validated under typical conditions observed in differentiated thyroid cancer (DTC) patients.
METHODS: Transversal spatial resolution and recovery measurements with (124)I and with fluorine-18 ((18)F) as the reference were performed using isotope-containing line sources embedded in water and six isotope-containing spheres 9.7 to 37.0 mm in diameter placed in water-containing body and cylinder phantoms. The cylinder phantom spheres were filled with (18)F only. Measurements in two-dimensional (2D) and three-dimensional (3D) modes were performed using both stand-alone PET (EXACT HR(+)) and combined PET/CT (BIOGRAPH EMOTION DUO) systems. Recovery comparison measurements were additionally performed on a GE ADVANCE PET system using the cylinder phantom. The recovery coefficients were directly determined using the activity concentration of circular regions of interest divided by the prepared activity concentration determined by the dose calibrator. The recovery correction method was validated using three consecutive scans of the body phantom under our (124)I PET(/CT) protocol for DTC patients.
RESULTS: Compared with that of (18)F, transversal spatial resolution of (124)I was slightly, but statistically significantly degraded (7.4 mm vs. 8.3 mm, P<0.002). Using the body phantom, recovery was lower for (124)I than for (18)F in both 2D and 3D modes. The (124)I recovery coefficient of the largest sphere was significantly higher in 2D than in 3D mode (81% vs. 75%, P=0.03). Remarkably, the (18)F recovery coefficient for the largest sphere significantly deviated from unity (range of 87%-93%, P<0.004) for all scanners but the GE ADVANCE. The maximum range of inaccuracy of the measured (124)I activity concentration under in vivo conditions after applying partial volume correction was +/-10% for spheres > or =12.6 mm in diameter.
CONCLUSIONS: Recovery correction is mandatory for (124)I PET quantification, even for large structures. To ensure accurate dosimetry, thorough absolute recovery measurements must be individually established for the particular PET scanner and radionuclide to be used.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17929014     DOI: 10.1007/s00259-007-0554-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  22 in total

1.  Recovery correction for quantitation in emission tomography: a feasibility study.

Authors:  L Geworski; B O Knoop; M L de Cabrejas; W H Knapp; D L Munz
Journal:  Eur J Nucl Med       Date:  2000-02

2.  PET quantitation and imaging of the non-pure positron-emitting iodine isotope 124I.

Authors:  H Herzog; L Tellman; S M Qaim; S Spellerberg; A Schmid; H H Coenen
Journal:  Appl Radiat Isot       Date:  2002-05       Impact factor: 1.513

3.  Quantitative imaging and correction for cascade gamma radiation of 76Br with 2D and 3D PET.

Authors:  Mark Lubberink; Harald Schneider; Mats Bergström; Hans Lundqvist
Journal:  Phys Med Biol       Date:  2002-10-07       Impact factor: 3.609

4.  Performance of a block detector PET scanner in imaging non-pure positron emitters--modelling and experimental validation with 124I.

Authors:  S Robinson; P J Julyan; D L Hastings; J Zweit
Journal:  Phys Med Biol       Date:  2004-12-21       Impact factor: 3.609

5.  (124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution.

Authors:  Andreas Bockisch; Lutz Freudenberg; Sandra Rosenbaum; Walter Jentzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

6.  Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution.

Authors:  C S Levin; E J Hoffman
Journal:  Phys Med Biol       Date:  1999-03       Impact factor: 3.609

7.  Performance characteristics of a whole-body PET scanner.

Authors:  T R DeGrado; T G Turkington; J J Williams; C W Stearns; J M Hoffman; R E Coleman
Journal:  J Nucl Med       Date:  1994-08       Impact factor: 10.057

8.  Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.

Authors:  Susanne M Eschmann; Gerald Reischl; Kilian Bilger; Juergen Kupferschläger; Marcel H Thelen; Bernhard M Dohmen; Hariolf Besenfelder; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-27       Impact factor: 9.236

9.  Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.

Authors:  Heiko Schöder; Yusuf E Erdi; Kenneth Chao; Mithat Gonen; Steven M Larson; Henry W D Yeung
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

10.  124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.

Authors:  L S Freudenberg; W Jentzen; R Görges; T Petrich; R J Marlowe; J Knust; A Bockisch
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

View more
  24 in total

1.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting.

Authors:  M Lassmann; C Chiesa; G Flux; M Bardiès
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-27       Impact factor: 9.236

2.  Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system.

Authors:  Rebecca A Gregory; Claire A Hooker; Mike Partridge; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-14       Impact factor: 9.236

Review 3.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

4.  Effect of the positron range of 18F, 68Ga and 124I on PET/CT in lung-equivalent materials.

Authors:  Gerrit J Kemerink; Mariëlle G W Visser; Renee Franssen; Emiel Beijer; Mariangela Zamburlini; Servé G E A Halders; Boudewijn Brans; Felix M Mottaghy; Gerrit J J Teule
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-02       Impact factor: 9.236

5.  The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.

Authors:  Walter Jentzen; Dorothee Balschuweit; Jochen Schmitz; Lutz Freudenberg; Ernst Eising; Thomas Hilbel; Andreas Bockisch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

Review 6.  Accuracy and precision of radioactivity quantification in nuclear medicine images.

Authors:  Eric C Frey; John L Humm; Michael Ljungberg
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

7.  Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.

Authors:  Scott M Knowles; Kirstin A Zettlitz; Richard Tavaré; Matthew M Rochefort; Felix B Salazar; David B Stout; Paul J Yazaki; Robert E Reiter; Anna M Wu
Journal:  J Nucl Med       Date:  2014-02-06       Impact factor: 10.057

Review 8.  Quantitative imaging of 124I and 86Y with PET.

Authors:  Mark Lubberink; Hans Herzog
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

9.  Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.

Authors:  Joseph J Grudzinski; Ronald R Burnette; Jamey P Weichert; Robert Jeraj
Journal:  Cancer Biother Radiopharm       Date:  2010-08       Impact factor: 3.099

10.  Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Authors:  Walter Jentzen; Robert F Hobbs; Alexander Stahl; Jochen Knust; George Sgouros; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.